{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:54:27Z","timestamp":1775624067292,"version":"3.50.1"},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"9","license":[{"start":{"date-parts":[[2016,5,10]],"date-time":"2016-05-10T00:00:00Z","timestamp":1462838400000},"content-version":"unspecified","delay-in-days":617,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infect. Control Hosp. Epidemiol."],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:sec id=\"S0899823X00192839_abs1\"><jats:title>Background.<\/jats:title><jats:p>Patients in the neonatal intensive care unit (NICU) are at high risk for healthcare-associated infections. Variability in reported infection rates among NICUs exists, possibly related to differences in prevention strategies. A better understanding of current prevention practices may help identify prevention gaps and areas for further research.<\/jats:p><\/jats:sec><jats:sec id=\"S0899823X00192839_abs2\"><jats:title>Methods<\/jats:title><jats:p>We surveyed infection control staff in NICUs reporting to the National Healthcare Safety Network (NHSN) to assess strategies used to prevent methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) transmission and central line\u2013associated bloodstream infections in NICUs.<\/jats:p><\/jats:sec><jats:sec id=\"S0899823X00192839_abs3\"><jats:title>Results<\/jats:title><jats:p>Staff from 162 of 342 NICUs responded (response rate, 47.3%). Most (92.3%) NICUs use central line insertion and maintenance bundles, but maintenance practices varied, including agents used for antisepsis and frequency of dressing changes. Forty-two percent reported routine screening for MRSA colonization upon admission for all patients. Chlorhexidine gluconate (CHG) use for central line care for at least 1 indication (central line insertion, dressing changes, or port\/cap antisepsis) was reported in 82 NICUs (51.3%). Among sixty-five NICUs responding to questions on CHG use restrictions, 46.2% reported no restrictions.<\/jats:p><\/jats:sec><jats:sec id=\"S0899823X00192839_abs4\"><jats:title>Conclusions<\/jats:title><jats:p>Our survey illustrated heterogeneity of CLABSI and MRSA prevention practices and underscores the need for further research to define optimal strategies and evidence-based prevention recommendations for neonates.<\/jats:p><jats:p><jats:italic>Infect Control Hosp Epidemiol<\/jats:italic> 2014;35(9):1126-1132<\/jats:p><\/jats:sec>","DOI":"10.1086\/677636","type":"journal-article","created":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T20:14:20Z","timestamp":1406319260000},"page":"1126-1132","source":"Crossref","is-referenced-by-count":16,"title":["Infection Prevention Practices in Neonatal Intensive Care Units Reporting to the National Healthcare Safety Network"],"prefix":"10.1017","volume":"35","author":[{"given":"Susan N.","family":"Hocevar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda C.","family":"Lessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Conover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Gorwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2016,5,10]]},"reference":[{"key":"S0899823X00192839_ref10","doi-asserted-by":"publisher","DOI":"10.1086\/653615"},{"key":"S0899823X00192839_ref3","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31819988bf"},{"key":"S0899823X00192839_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0196-6553(93)90202-F"},{"key":"S0899823X00192839_ref2","volume-title":"Fifth Decennial International Conference on Healthcare-Associated Infections","author":"Lessa","year":"2010"},{"key":"S0899823X00192839_ref11","doi-asserted-by":"publisher","DOI":"10.1086\/655994"},{"key":"S0899823X00192839_ref8","doi-asserted-by":"publisher","DOI":"10.1086\/673447"},{"key":"S0899823X00192839_ref22","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.6.2294-2297.2001"},{"key":"S0899823X00192839_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3283297b68"},{"key":"S0899823X00192839_ref14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-1382"},{"key":"S0899823X00192839_ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.153"},{"key":"S0899823X00192839_ref17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1449"},{"key":"S0899823X00192839_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2007.10.006"},{"key":"S0899823X00192839_ref23","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq291"},{"key":"S0899823X00192839_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2011.04.011"},{"key":"S0899823X00192839_ref15","doi-asserted-by":"publisher","DOI":"10.1086\/598341"},{"key":"S0899823X00192839_ref21","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.2000.0930"},{"key":"S0899823X00192839_ref4","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2009.119"},{"key":"S0899823X00192839_ref19","unstructured":"US Food and Drug Administration (FDA). 2% Chlorhexidine Gluconate (CHG) Cloth: Safety Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)\u2014May 2012. Silver Spring, MD: FDA, 2012. http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/Safety-RelatedDrugLabelingChanges\/ucm307387.htm."},{"key":"S0899823X00192839_ref9","doi-asserted-by":"publisher","DOI":"10.1086\/655017"},{"key":"S0899823X00192839_ref7","unstructured":"SurveyMonkey. http:\/\/www.surveymonkey.com. Accessed April 8, 2013."},{"key":"S0899823X00192839_ref16","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2009.172"},{"key":"S0899823X00192839_ref5","article-title":"Guidelines for the prevention of intravascular catheter-related infections","volume":"52","author":"O\u2019Grady","year":"2011","journal-title":"Clin Infect Dis"},{"key":"S0899823X00192839_ref13","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-2873"}],"container-title":["Infection Control &amp; Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0899823X00192839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T01:14:16Z","timestamp":1555895656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0899823X00192839\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9,1]]}},"alternative-id":["S0899823X00192839"],"URL":"https:\/\/doi.org\/10.1086\/677636","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,1]]}}}